Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil (BN101) in Chronic GVHD After ≥1 Prior Systemic Therapy
CTR20210663Phase 2Completed
- Sponsor
- BK Pharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by BK Pharmaceuticals. Started Apr 2021; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20210663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210663.